Xilio Therapeutics, Inc. (XLO)
9.05
+0.04
(+0.44%)
USD |
NASDAQ |
Oct 09, 16:00
9.08
+0.03
(+0.33%)
After-Hours: 20:00
Xilio Therapeutics Net Income (Quarterly) : -6.373M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -6.373M |
| March 31, 2026 | -9.529M |
| December 31, 2025 | 10.36M |
| September 30, 2025 | -16.29M |
| June 30, 2025 | -15.84M |
| March 31, 2025 | -13.26M |
| December 31, 2024 | -13.09M |
| September 30, 2024 | -14.02M |
| June 30, 2024 | -13.92M |
| March 31, 2024 | -17.20M |
| December 31, 2023 | -17.66M |
| September 30, 2023 | -16.75M |
| June 30, 2023 | -19.36M |
| Date | Value |
|---|---|
| March 31, 2023 | -22.65M |
| December 31, 2022 | -22.47M |
| September 30, 2022 | -19.79M |
| June 30, 2022 | -24.61M |
| March 31, 2022 | -21.35M |
| December 31, 2021 | -19.70M |
| September 30, 2021 | -16.25M |
| June 30, 2021 | -23.18M |
| March 31, 2021 | -16.67M |
| December 31, 2020 | -20.77M |
| September 30, 2020 | -14.82M |
| June 30, 2020 | -11.51M |
| March 31, 2020 | -8.118M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Cue Biopharma, Inc. | -153.07M |
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 18.69M |
| Total Expenses (Quarterly) | 25.06M |
| EPS Diluted (Quarterly) | -0.3284 |
| Enterprise Value | -70.19M |
| Gross Profit Margin (Quarterly) | 98.23% |
| Profit Margin (Quarterly) | -34.09% |
| Earnings Yield | -18.63% |
| Normalized Earnings Yield | -19.89 |